117,552 Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Purchased by Federated Hermes Inc.

Federated Hermes Inc. purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 117,552 shares of the company's stock, valued at approximately $2,645,000. Federated Hermes Inc. owned about 0.24% of Enliven Therapeutics as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in Enliven Therapeutics by 14.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock worth $233,000 after buying an additional 1,275 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Enliven Therapeutics by 12.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company's stock worth $668,000 after purchasing an additional 2,944 shares during the period. The Manufacturers Life Insurance Company grew its position in Enliven Therapeutics by 25.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company's stock worth $441,000 after purchasing an additional 3,518 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Enliven Therapeutics in the fourth quarter valued at $97,000. Finally, Swiss National Bank raised its holdings in shares of Enliven Therapeutics by 13.9% in the fourth quarter. Swiss National Bank now owns 41,873 shares of the company's stock valued at $942,000 after buying an additional 5,100 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Insider Activity at Enliven Therapeutics

In related news, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction on Friday, February 7th. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the transaction, the chief operating officer now directly owns 329,977 shares of the company's stock, valued at approximately $7,236,395.61. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $21.59, for a total value of $70,167.50. Following the sale, the chief financial officer now owns 13,000 shares in the company, valued at approximately $280,670. The trade was a 20.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,751 shares of company stock worth $1,178,263 over the last 90 days. Company insiders own 29.20% of the company's stock.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN traded up $0.46 during mid-day trading on Friday, reaching $16.53. The stock had a trading volume of 171,768 shares, compared to its average volume of 266,202. The firm has a market capitalization of $810.04 million, a price-to-earnings ratio of -8.70 and a beta of 1.03. The business has a 50 day simple moving average of $19.87 and a 200 day simple moving average of $23.08. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. As a group, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright increased their price objective on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research report on Friday, March 21st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.